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Summary 
Non-Ap component of Alzheimefs disease amyloid 
(NAC) is the second component in the amyloid from 
brain tissue of patients affected with Alzheimer's dis- 
ease. Its precursor protein (NACP) was shown to be 
a'brain-specific protein. In rat brain, NACP was more 
abundant in the neocortex, hippocampus, olfactory 
bulb, striatum, thalamus, and cerebellum and less 
abundant in the brain stem. Confocal laser microscopy 
analysis revealed that anti-NACP immunostaining was 
colocalized with synaptophysin-immunoreactive pre- 
synaptic terminals. Ultrastructural analysis showed 
that NACP immunoreactivity was associated with syn- 
aptic vesicles. NACP sequence showed 95% identity 
with that of rat synuclein 1, a synapUc/nuclear protein 
previously identified in rat brain, and good homology 
with Torpedo synuclein from the electric organ syn- 
apse and bovine phosphoneuroprotein 14 (PNP-14), a 
brain-specific protein present in synapses. Therefore, 
NACP is a synaptic protein, suggesting that synaptic 
aberration observed in senile plaques might be in- 
volved in amyloidogenesis in Alzheimer's disease. 
Introduction 
Alzheimer's disease (AD) is a progressive neurodegenera- 
tive disorder characterized by neuronal loss and gliosis, 
which are accompanied by amyloid deposits at the core 
of senile plaques and on the vessel walls (Joachim and 
Selkoe, 1992; Price et al., 1992). A 39-43 amino acid poly- 
peptide, AI3, was found as a component of amyloid in AD 
(Glenner and Wong, 1984; Masters et al., 1985; Mori et al., 
1992). Recent immunohistochemical studies have shown 
that, in addition to A~, many other proteins are associated 
with AD amyloid, including al-antichymotrypsin (Abraham 
et al., 1988), apolipoprotein E (Namba et al., 1991; Stritt- 
matter et al., 1993), complement proteins (Ishii and Haga, 
1992), serum amyloid P (Duong et al., 1989), SP-40,40 
(Choi-Miura et al., 1992), heparan sulfate proteoglycan 
(Snow et al., 1988), immunoglobulins (Ishii et al., 1975), 
gamma-trace peptide (Vinters et al., 1990), and lysosomal 
proteinases (Cataido et al., 1990, 1994). 
Recently, the Non-Al~ component of AD amyloid, NAC, 
consisting of at least 35 amino acids, was found in the 
amyloid-enriched fraction of AD brain, and antisera raised 
against NAC were found to stain both senile plaque amy- 
Ioid and vessel amyloid. NAC, along with AI3, was copuri- 
fled with amyloid in the SDS-insoluble fraction and se- 
quenced biochemically, which makes NAC distinct from 
other amyloid-associated components that are detected 
only by immunological methods, suggesting that NAC may 
be tightly associated with AI3 and may have a role in amy- 
Ioidogenesis in AD brain. A cDNA encoding the precursor 
protein of NAC (NACP) was cloned (U~da et al., 1993), 
and it was found that NACP is composed of 140 amino 
acids. NACP is recovered in the cytosolic fraction of hu- 
man brain homogenate as a protein with an apparent mo- 
lecular mass of 19,000 Da. NACP has seven repeated 
KTKEGV motifs but no signal peptide sequence nor N-linked 
glycosylation sites. NAC is located in the most hydropho- 
bic portion of the NACP molecule. To evaluate further the 
role of NAC and NACP in AD pathogenesis, the investiga- 
tion of physiological function of NACP is required. As a 
first step toward this effort, we localized NACP using im- 
munohistochemical techniques. In this article, we show 
that NACP is located in presynaptic terminals in brain. 
Because the precursor protein of AIS, APP, is also a presyn- 
aptic protein, our finding indicates the participation of two 
presynaptic proteins in amyloid formation in AD and raises 
the possibility that presynaptic pathology in senile plaques 
may be involved in amyloidogenesis in AD. 
Results 
Specificity of Antibody in Western Blot 
Both antibodies, anti-NACP(1-9) against the NACP N-ter- 
minus and anti.NACP(131-140) against NACP C-terminus 
(Figure 1A), recognized a unique doublet band with molec- 
ular mass around 19,000 Da, located mainly in the cyto- 
solic fraction of human and rat brain homogenates (Figure 
1B). The lower band of this NACP doublet comigrated with 
recombinant NACP made in Escherichia coli. Comparison 
of the intensity of NACP staining in brain homogenates 
and the recombinant NACP preparation showed that as 
much as 0.5%-1.0% of the cytosolic protein was NACP. 
The staining of each antibody was abolished by incubating 
the antibody with its corresponding peptide (Figure 1B). 
Under the same experimental conditions, essentially all 
synaptophysin immunoreactivity was recovered in the par- 
ticulate fractions, demonstrating that all synaptic vesicles 
were in the particulate fractions. Longer exposure of an- 
ti-NACP-stained blots showed faint NACP bands in the 
particulate fractions, leaving the possibility that a small 
fraction of NACP proteins may be associated with the par- 
ticulate fractions. 
Neuron 
468 
A N; \ 
MDVFMKGLS 
anti-NACP(1-9) 
B 
kDa 
49,5 
32.5 "~ 
27.5 -~ 
18.5 ~D 
61 
I 
NAC 
95 
I 
~t  
//•"•1"• C 
EGYQDYEPEA 
anti-NACP(131-140) 
123456 123456 123456 123455 34  
anti-NACP(1-9) anti-NACP(131-140) SY3S 
+ peptide + peptide 
Figure 1. Specificity of Anti-NACP Antibodies 
(A) Schematic presentation ofNACP and its subdomain used to raise 
the antisera, anti-NACP(1-9) and anti-NACP(131-140). The NAC frag- 
ment (35 amino acids) originally found in the SDS-insoluble amyloid- 
enriched fraction of AD brain tissue is located in the middle of NACP 
(61-95). 
(B) Western blot of cytosolic and particulate fractions from the homoge- 
nate of human brain, rat brain, and E. coli expressing human NACP. 
Lane 1, vector control E. coli homogenate; lane 2, NACP expressing 
E. coil homogenate; lane 3, cytosolic fraction of human brain; lane 4, 
particulate fraction of human brain; lane 5, cytosolic fraction of rat 
brain; lane 6, particulate fraction of rat brain. Anti-NACP(1-9) and 
anti-NACP(131-140) labeled the 19,000 Da doublet (arrow) mainly in 
cytosolic fractions. These immunoreactive bands were lost with preab- 
sorption by the corresponding peptide (+ peptide). Anti-synaptophysin 
antibody, SY38, labeled the 38,000 Da protein (arrowhead) in the par- 
ticulate fraction. 
NACP Is Localized in the Presynaptic Terminals 
Using the streptavidin-biotin-peroxidase (SAB) staining 
method, rat brain sections were immunostained by anti- 
NACP(131-140) and anti-NACP(1-9) antibodies. The in- 
tensity of immunostaining with anti-NACP(131-140) was 
relatively stronger in the cerebral cortex (layers II, III, and 
V), olfactory region, caudoputamen, nucleus accumbens, 
hippocampus, and cerebellar cortex than in the thalamus 
and brain stem (Figure 2A). The immunostaining pattern 
of the brain using anti-NACP(1-9) antibody was indistin- 
guishable from that of anti-NACP(131-140) (data not 
shown). Immunolabeling was abolished by preincubation 
of the antibodies with the corresponding peptide (data not 
shown). 
Throughout the various cortical and subcortical areas 
of the rat brain, anti-NACP immunostained the neuropil 
in a characteristic punctate pattern (Figures 2B-2D). Neu- 
ronal cell bodies, glial cells, and blood vessels were not 
immunostained. In the cerebral cortex, hippocampus, and 
cerebellar cortex, anti-NACP immunostained the neuropil 
following laminar patterns of arrangement (Figures 2A- 
2D). Ultrastructural analysis of sections immunolabeled 
with NACP confirmed the synaptic localization of this pro- 
tein and showed that NACP was in close vicinity of, or in 
association with, the clear synaptic vesicles (Figures 2E 
and 2F). 
Laser scanning confocal microscopic analysis of sec- 
tions double irnmunolabeled with antibodies against NACP 
and synaptophysin showed that both markers colocalized 
in the great majority of the presynaptic terminals (Figure 3; 
Figure 4). In the neocortex, hippocampus, basal ganglia, 
olfactory region, and thalamus, between 70% and 100% 
of the axosomatic, axoaxonic, and axodendritic terminals 
contained both markers (Figure 5). In contrast, in the deep 
cerebellar and brain stem nuclei, although synaptophysin 
and NACP colocalization in axodendritic terminals was 
relatively common, only a small proportion of the axoso- 
matic terminals contained NACP (Figure 3; Figure 4; Fig- 
ure 5). In both cortical and subcortical regions, a small 
proportion of terminals was synaptophysin positive and 
NACP negative (Figure 4D-41; Figure 5). Occasionally, 
punctate structures displayed NACP immunoreactivity but 
not synaptophysin immunoreactivity. Serial section analy- 
sis showed that these neuritic structures actually corres- 
ponded to the terminal segments of axons. Abundant 
NACP immunoreactivity was observed associated with 
specialized synaptic complexes, including the glomeruli 
of the olfactory bulb (Figure 3E), the glomeruli of the cere- 
bellar granular layer (Figure 3H), and the mossy fiber syn- 
apses (Figure 4B). 
Quantification of NACP and Synaptophysin 
NACP protein was detected as a 19,000 Da doublet on an 
immunoblot of the cytosolic fraction of brain homogenate 
(Figure 1B). Synaptophysin protein bands were detected 
at 38,000 Da in the particulate fraction of brain sample by 
a mouse monoclonal antibody, SY38 (Figure 1B). Distribu- 
tion of each protein was shown as a relative amount, with 
the amount in the frontal cortex set at 1. As shown inFigure 
6, consistent with immunohistochemical results shown in 
Figure 2A and data of quantitation of NACP synapses 
shown in Figure 5, the concentration of NACP was high 
in the telencephalon (end-brain regions, including the ol- 
factory bulb, frontal cortex, striatum, and hippocampus), 
intermediate in the hypothalamus and thalamus, and low 
in the midbrain, cerebellum, pone, medullaoblongata, and 
pituitary. Synaptophysin was more evenly distributed in 
most regions of the brain. However, the amount of this 
protein in the pituitary was small. 
NACP Homologies 
Computer search of the DNA sequence database (EMBL/ 
GenBank Libraries) revealed that some proteins had se- 
quences homologous to NACP (Figure 7). A search in pep- 
tide sequence databases for homologous sequences of
the deduced 140 amino acid precursor primary sequence 
was performed at NCBI (National Center for Biotechnology 
Information, Bethesda, MD) using the BLAST network ser- 
vice (Altschul et al., 1990). NACP was found to be homolo- 
gous to synucleins from human brain (Jakes et al., 1994), 
NACP Is a Presynaptic Protein 
469 
A 
Figure 2. Distribution ofNACP in Rat Brain Detected by Anti-NACP(131-140) 
(A-D) Low magnification view of a sagittal brain section (A) shows that NACP immunoreactivity detected by the streptavidin-biotin-peroxidase 
(SAB) method was relatively strong in the neocortex, olfactory region, caudoputamen, hippocampus, and cerebellar cortex compared with the 
thalamus and brain stem. Higher magnification a alysis howed a characteristic granular immunoreactivity throughout the brain, including the 
cerebellar cortex (B), the molecular layer of the hippocampal dentate gyrus (C), and the cerebral cortex (D). Closed arrows in (B) indicate axosomatic 
synapses around Purkinje cells, and open arrows indicate glomerular complex. CB, cerebellum; CX, cerebral cortex; GCL, granular cell layer; 
HIP, hippocampus; ML, molecular layer; OB, olfactory bulb; STR, striatum. 
(E and F) Electron micrographs showing the localization of NACP in presynaptic terminals. 
(E) Preembedding NACP immunostaining detected by DAB. The staining was confined to presynaptic terminals. (F) Ultrathin sections from the 
hippocampal CA3 region were immunolabeled with anti-NACP(131-140) followed by 5 nm gold anti-rabbit IgG. Gold-labeled NACP (arrows) was 
detected on or close to presynaptic vesicles. The inset is a higher magnification toshow the localization of gold (arrow) an presynaptic vesicles. 
Bar, 0.5 I~m (E and F). 
rat brain (Maroteaux and Scheller, 1991), and the electric 
organ synapse of Torpedo californica, the Pacifi0 electric 
ray (Maroteaux et al., 1988), and to bovine phosphoneuro- 
protein 14 (PNP-14), a brain-specific protein present in 
synapses around neurons but not in glial cells and Purkinje 
cell bodies (Nakajo et al., 1993). These small, acidic, brain- 
specific proteins have common repetitive sequence motifs 
and similar hydrophobic profiles. NACP shares a 95% 
identity with rat synuclein, form 1 (SYN1); of the seven 
mismatches, three are conservative. As with SYN1, sy- 
nuclein 13 (synl~), and PNP-14, NACP is essentially hydro- 
philic, with the exception of the hydrophobic NAC region 
in the center of the molecule. Common to their N-terminal 
halves are the repeat motifs, KTKEGV (Maroteaux et al., 
1988), of which seven units can be identified in NACP. All 
prolines of these proteins are contained in their C-terminal 
regions, which are also rich in glutamic acid residues. The 
latter contribute to their acidity. Arginine, cysteine, and 
tryptophan are notably absent in all these proteins. Rat 
SYN3 and human EST01420, identified by random se- 
quencing of human brain cDNAs (Adams et al., 1992), had 
homologous equence to the N-terminal portion of NACP, 
but neither of them included the NAC portion. Homo sapi- 
ens putatively transcribed partial sequence (HSPTPS), 
found by the MRC Human GenomeMapping Project, had 
a homologous sequence corresponding to the NAC por- 
tion of NACP. 
Discussion 
To investigate the distribution of NACP found as a pre- 
cursor of the second major amyloid component in AD, 
two antibodies recognizing the N- and C-terminals of 
NACP were prepared. Both showed specificity in Western 
blot and immunohistochemical studies. These antibodies 
against human NACP recognized rat NACP comigrating 
at the same molecular mass as human NACP of 19,000 
Da, indicating that the N- and C-terminals are both con- 
served in these species. In Western blots, the protein band 
of human and rat NACP showed doublet bands, although 
bacteria-expressed NACP protein showed only a single 
band with a faint tailing of degraded products. It is conceiv- 
able that in eukaryotic ells NACP may undergo posttrans- 
lational modification, such as phosphorylation, as was 
suggested for PNP-14 (Nakajo et al., 1993; Shibayama- 
Imazu et al,, 1993), for NACP has a PKC target motif 
(KTKEGV) seven times within its sequence (Kennelly and 
Krebs, 1991). It is also possible that NACP is a member 
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Figure 3. Laser Scanning Confocal Microscopy of Sections Double-Labeled for SY38 and NACP(131-140) 
Mouse monoclonal anti-synaptophysin (SY38) is labeled with fluorescein isothiocyanate and shown in green (A, D, and G); NACP(131-140) is 
labeled with Texas red (B, E, and H). (C), (F), and (I) correspond to the electronically merged image; colocalization of NACP with synaptophysin 
is represented in yellow. (A-C) Neocortex; (D-F) glorneruli of the olfactory bulb; (G-I) cerebellar cortex. Bar, 15 tam. 
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Figure 5. Computer-Aided Quantitation of Colocalization of NACP 
with Synaptophysin the Presynaptic Terminals 
In the Cortical regions, a large percentage of the synaptophysin- 
immunoreactive terminals contained NACP. In Contrast, in subcortical 
regions, a lower proportion of the synaptophysin-immunolabeled axo- 
SOmatic nerve terminals contained NACP. 
of a group of closely related proteins, all of which may be 
detected by the antI-NACP antibody that we employed 
(Jakes et al., 1994). 
NACP was found to be distributed with a unique pattern 
in the brain, whereas synaptophysin was found to be dis- 
tributed more ubiquitously. Both immunohistochemical 
and biochemical data demonstrated that NACP is rela- 
tively abundant in the telencephalon, including the olfac- 
tory bulb, cerebral cortex, striatum, and hippocampus, and 
is expressed moderately in the thalamus. NACP was re- 
ported by U~la et al. (1993), using Northern blot analysis, 
to be produced mainly in the central nervous system. To- 
gether, these data suggest that NACP might have some 
characteristic function in the telencephalon, which may 
be acquired during brain development. 
In the central nervous system, APP, the precursor of 
the major amyloid component AI3, is found in neurons, 
gila, and ependymal and mantle cells (Card et al., 1988; 
Kawarabayashi et al., 1991). This protein is reported to 
be localized in the cell body, especially on or near the 
plasma membrane (Shivers et al., 1988), in Golgi (Capor- 
aso et al., 1994), or transported to a synaptic site by fast 
anterograde axonal transport (Koo et al., 1990; Schubert 
et al., 1991). Differing from the distribution of APP, NACP 
was found in close vicinity of the synaptic vesicles in pre- 
synaptic terminals, but not in the cell body of neurons. 
This distribution was similar to that of synaptophysin iden- 
tified by a mouse monoclonal antibody, SY38 (Wieden- 
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Figure 6. Western Blot Quantitation ofNACP and Synaptophysin 
Immunostalning ofNACP and synaptophysin bands was carried out 
using anti-NACP(131-140) and mouse monoclonal ntibody SY38, 
respectively. Signal intensity was quantified by scanning with a densi- 
tometer. Each value is shown as a relative amount of protein ormal- 
ized to the value in frontal cortex. NACP is highly concentrated in
olfactory bulb, frontal cortex, striatum, and hippocampus, whereas 
synaptophysin s distributed more uniformly throughout the brain. 
mann and Franke, 1985). Synaptophysin is a synaptic ves- 
icle protein used as a "presynaptic marker" (Masliah et al., 
1991b, 1992a). Double immunostaining with anti-synapto- 
physin suggests that NACP is also specific to presynaptic 
terminals and may have a role for presynaptic function, 
involving synaptic vesicles. Because synaptophysin is an 
integral membrane protein of synaptic vesicles, it is de- 
tected in the particulate fraction in Western blot. On the 
other hand, NACP was found mainly in the cytosolic frac- 
tion. Therefore, it is possible that NACP is loosely associ- 
ated with the membrane or membrane-binding proteins 
of synaptic vesicles as a peripheral protein like F1-ATPase 
on the mitochondrial inner membrane (Horstman and 
Racker, 1970). The hydrophobic domain of NACP includ- 
ing the NAC portion might be the region responsible for 
this putative association with the synaptic vesicles. 
NACP showed high homology with the human synuclein 
13, rat synucleins, Torpedo synuclein, and bovine PNP-14. 
Synucleins and PNP-14 are neuron-specific proteins 
found to be concentrated in presynaptic terminals (Maro- 
teaux et al., 1988; Maroteaux and Scheller, 1991; Nakajo 
et al., 1993; Jakes et al., 1994). Two additional human 
proteins, the identities of which are not known, were also 
found to show homology with NACP. The existence of 
several alternatively spliced forms and other homologous 
sequences suggests that NACP, synucleins, and PNP-14 
are members of a protein family. In previous reports sy- 
nucleins were found not only in presynaptic terminals but 
Figure 4. Laser Scanning Confocal Microscopy of Sections Double-Labeled for SY38 and NACP(131-140) 
Mouse monodonal anti-synaptophysin (SY38) is labeled with fluorescein isothiocyanate and shown in green (A, D, and G); NACP(131-140) is 
labeled with Texas red (e, E, and H). (C), (F), and (I) Correspond to the electronically merged image; colocalization ofNACP with synaptophysin 
is represented inyellow. (A-C) Mossy fiber terminals in the hippocampal CA3; (D-F) nucleus pontis; (G-I) dentate nuclei of the cerebellum. Bar, 
15 p.m. 
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Figure 7. NACP Sequence Homologies 
Number efers to the amino acids from the first methionine of NACP. 
The NAC portion found in theAD amyloid is underlined. Identical amino 
acids among proteins are indicated by dots. Insertions (/) were intro- 
duced to maximize the homology. Only different amino acids were 
shown in the proteins, except for NACP. 13SYN, 13-synuclein; SYN1, 
synuclein 1; SYN2, synuclein 2; SYN3, synuclein 3; bovine PNP-14, 
bovine phosphoneuroprotein 14; Human EST, EST01420 found by 
random sequencing of human brain cDNAs (Adams et al., 1992); 
HSPTPS, Homo sapiens putatively transcribed partial sequence found 
by UK-HGMP; Torpedo SYN, Torpedo synuclein. 
also in nuclei in Torpedo, the reason why the proteins 
bear the name "synuclein." However, our affinity-purified 
antibodies revealed that rat NACP is distributed only in 
presynaptic terminals, not in nuclei. PNP-14 was also re- 
ported to be localized uniquely to presynaptic terminals. 
The reasons for these different results may reside in the 
differences of the antisera and the animals. The antiserum 
recognizing both the nuclear and synaptic proteins was 
raised using the fusion protein of Torpedo synuclein- 
13-galactosidase and was used without affinity purification. 
This antiserum might have cross-reactivity with the other 
Torpedo proteins in the nucleus. In fact, this antiserum 
against "synuclein" did not stain a single band on a West- 
ern blot of crude homogenate. On the other hand, some 
isoforms of synuclein might be distributed in nuclei specifi- 
cally in the fish. Our antisera, anti-NACP(1-9) and anti- 
NACP(131-140), were raised using the synthetic peptides 
of the human NACP N- and C-terminal sequences and 
purified with the corresponding peptides. On Western 
blots, our affinity-purified antibodies recognized uniquely 
the bands corresponding to NACP in both rat and human 
brain homogenate. The data with our specific antibodies 
suggest that NACP is a presynaptic protein in the mamma- 
lian brain, and the name "synuclein" may not be appro- 
priate for this protein. 
It has been reported that presynaptic damage and struc- 
tural abnormalities are found in the AD brain, with the 
most pronounced changes in senile plaques, and that this 
synaptic damage correlates well with cognitive impairment 
(Terry et al., 1991; Masliah et al., 1992a). The relationship 
between synaptic damage within senile plaques and amy- 
Ioidogenesis is not clear. It is noteworthy that the compo- 
nents located at the synaptic site are associated with neu- 
ritic alteration and plaque formation in AD. APP, the 
precursor of the major constituent of AD amyloid, accu m u- 
lates in dystrophic neurites in a subset of senile plaques 
(Shoji et al., 1990; Cole et al., 1991; Joachim et al., 1991; 
Masliah et al., 1992b). Chromogranin A, a marker protein 
for the large dense-core vesicles in presynaptic terminals, 
and synaptophysin were both found in dystrophic neurites 
of AD senile plaques, and the ratio of chromogranin A to 
synaptophysin was increased in AD (Wailer et al., 1990; 
Brion et al., 1991; Munoz, 1991; Lassmann et al., 1992). 
GAP-43, a marker protein for both sprouting presynaptic 
terminal and growth cones, also accumulates in the dystro- 
phic neurite in senile plaques (Masliah et al., 1991 b). How- 
ever, peptide fragments derived from these presynaptic 
proteins were not detected in the amyloid, except for APP 
and NACP, possibly reflecting the absence and presence 
of an "amyloidogenic" sequence within these proteins. In 
addition to amyloid and neuronal components, both astro- 
glial and microglial cells are another prominent feature 
of senile plaques (Price et al., 1992). Glial components 
participate in the formation of plaques only at the late 
steps, and they are not found in diffuse plaques, the most 
primitive stage of plaques. As both AI3 and NAC are immu- 
nopositive in diffuse plaques, it is conceivable that meta- 
bolically abnormal presynaptic terminals which contain 
APP and NACP are already associated with diffuse plaques. 
Thus, synaptic abnormality might be closely related to the 
early stage of amyloidosis and plaque formation. Investi- 
gation of NAC and NACP may help elucidate further the 
molecular mechanisms of amyloidosis and synaptic alter- 
ation, and their interactions in AD brain. 
Experimental Procedures 
Antibodies against NACP 
Two peptide sequences, 9 amino acid N-terminal NACP (MDVFMK- 
GLS) and 10 amino acid C-terminal NACP (EGYQDYEPEA), were syn- 
thesized, with an additional cysteine at each C-terminus for conjuga- 
tion with the carrier protein keyhole limpet hemocyanin (Calbiochem, 
San Diego, CA; Green et al,, 1982), by a Rainin PS3 peptide synthe- 
sizer (Rainin, Woburn, MA) or an Applied Biosystems peptide synthe- 
sizer (Model 430A, Applied Biosystems, Foster City, CA) and purified 
by a Waters high performance liquid chromatograph (Model 600E, 
Waters, Milford, MA) with a YMC Pack R & D D-ODS column using 
0%-70% acetonitrile including 0.1% trifluoroacetic a id. Each peptide 
(10 rag) was conjugated with keyhole limpet hemocyanin (10 mg) in 
2 ml of phosphate-buffered saline (PBS; 0.01 M phosphate, 0.15 M 
NaCI [pH 7.4]) by 2.5 mg/ml m-maleimidobenzoyI-N-hydroxy- 
succinimide ster for 30 rain with stirring and dialyzed overnight 
against PBS using dialyzing tubing with a 5000-6000 Da cutoff to 
remove uncoupled peptide. A 200 I~g quantity of peptide, emulsified 
in Freund's complete adjuvant, was administered subcutaneously to
New Zealand rabbits, and 100 p~g of peptide mulsified in Freund's 
incomplete adjuvant was used subsequently several times at 2-3 week 
intervals for boosting. Antibodies were purified using affinity chroma- 
tography with immobilized corresponding peptide. Pierce Immuno- 
Pure Ag/Ab immobilization kit#1 (Pierce, Rockford, IL) was used for 
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antibody purification following the company-recommended protocol. 
Briefly, 1 mg of peptide was coupled to activated agarose in 0.1 M 
sodium cyanoborohydride. The 50% ammonium sulfate precipitate 
from 5 ml of serum was incubated with this affinity agarose overnight 
at 4°C. After several washings with PBS, specific antibody was eluted 
by 0.1 M glycine/HCI (pH 2.8). The protein-containing fractions were 
immediately neutralized with 1 M Tris-HCI (pH 9.5), and the protein 
peaks were pooled and dialyzed against PBS using dialyzing tubing 
with a 5000-6000 Da cutoff. The purified antibody raised to NACP 
(1-9) was named "anti-NACP(1-9)" and the one to NACP(131-140) 
was named "anti-NACP(131-140)." 
Bacterially Expressed Human NACP 
The bacterial NACP expression construct, pSENACP, was previously 
described (HBS6-1 ; Ueda et al., 1993). The E. coil HB 101 transformant 
harboring pSENACP was cultured in Luria-Bertani medium to mid-log 
phase, and isopropyl-l-thio-13-D-galactoside was added to a final con- 
centration of 0.5 mM and cultured for 4 hr. Cells were harvested by 
centrifugation and disrupted by sonication. The lysate was centrifuged 
at 100,000 x g at 4°C for 30 rain to recover the supernatant hat 
contained the NACP protein. The purity of the NACP protein in this 
preparation was about 10%. 
Specificity of Antibodies in Western Blot 
Western blot procedures were described previously (Masliah et al., 
1991 a). Briefly, human midfrontal cortex gray matter and young adult 
Sprague-Dawley rat frontal cortex were homogenized in 10 vol of 
homogenizing buffer (5 mM HEPES [pH 8.0], 0.32 M sucrose, 5 mM 
benzamidine, 2 mM ~-mercaptoethanol, 3 mM EGTA, 0.5 mM MgSO4, 
0.05% NAN3) containing protease inhibitors (10 i~g/ml eupeptin, 5 
~g/ml pepstatin A, 10 i~g/ml aprotinin, 10 mM phenylmethylsulfonyl 
fluoride) and phosphatase inhibitors (10 ~M sodium orthovanadate, 2 
mM KF, 1 pM okadaic acid) using a Teflon/glass homogenizer at 4°C. 
Homogenized samples were centrifuged at 100,000 x g for 1 hr at 
4°C. The supernatant was used as the cytosolic fraction, and the 
rehomogenized pellet in the original volume of homogenizing buffer 
was used as the particulate fraction. The soluble fraction of E. coil 
transfected with pSENACP was used as an "authentic" human NACP. 
As a negative control, the soluble fraction of the E. coil homogenate 
transfected with pSE380 was used (vector control). Protein concentra- 
tion was determined by Bradford assay (Bio-Rad protein assay, Bio- 
Rad, Hercules, CA) with a protocol recommended by the manufacturer. 
Protein from brain homogenate (40 Hg) and protein from E. coli homog- 
enate (1.5 ~g; containing about 150 ng of NACP) in Laemmli sample 
buffer (Laemmli, 1970) were electrophoresed on 16% SDS-polyacryl- 
amide gels and blotted to nitrocellulose membrane (Schleicher & 
Schuell, Inc., Keene, NH). The membrane was incubated in PBS with 
0.3% Tween-20 for 1 hr at room temperature to block nonspecific 
binding sites. The affinity-purified antibodies were diluted in PBS con- 
taining 1% bovine serum albumin (BSA) and 0.1% Tween-20 at the 
dilution of 1:100-1:30. The membrane was incubated with the antibody 
solution at 4°C overnight, washed in PBS containing 0.1% Tween-20, 
incubated with 0.5 p.Ci/ml iodinated protein A (ICN Pharmaceutical, 
Inc., Covina, CA) in PBS containing 3% BSA and 0.1% Tween-20 for 
1 hr, washed, wrapped, and apposed to Kodak X-Omat RP film at 
-80°C. Films were then developed with a Konica film developer. The 
specificity of each antibody was confirmed by the absence of a NACP 
band in Western blots incubated with antibody preabsorbed with each 
corresponding peptide with a ratio of 5 I~g peptide to 1 I11 of purified 
antibody. 
Immunocytochemistry and Laser Scanning Confocal 
and Immunoalectron Microscopy 
Sprague-Dawley rats weighing 250-300 g were deeply anesthetized 
by sodium pentobarbital (Nembutal, Abbott Laboratories, North Chi- 
cago, IL) and perfused transcardially with PBS and then with 4% para- 
formaldehyde in PBS for 20 rain, and the brain was removed and 
immediately placed in a postfixative, 4% paraformaldehyde solution, 
for 4 days at 4°C. The brain was immersed in a 30% sucrose solution 
in PBS for 4 days at 4°C, frozen in -40°C hexane, and cut into 20 
~m sections using a cryostat at -20°C. 
Immunohistochemistry was performed according to the modified 
SAB method. Sections were rinsed three times for 5 min each in PBS, 
incubated for 10 min in PBS containing 0.1% Triton X-100, and incu- 
bated for 20 min with 3% H202 to inhibit endogenous peroxidase. They 
were then incubated for 10 min with 10% normal goat serum (NGS; 
Nichirei, Tokyo, Japan) in PBS and incubated for 18 hr at 4°C with 
anti-NACP(1-9) or anti-NACp(131-140) antibody in PBS containing 
1% BSA. Sections were rinsed three times for 5 min each in PBS 
and incubated with biotinylated goat anti-rabbit IgG solution (Nichirei, 
Tokyo, Japan) for 10 min. They were then rinsed three times for 5 
rain in PBS, incubated with streptavidin-peroxidase olution (Nichirei, 
Tokyo, Japan) for 5 min, and rinsed three times for 5 min each in PBS. 
NACP-positive structures were visualized by incubating the tissue in 
0.05% diaminobenzidine (DAB) with 0.01% H202 in 0.61 M Tris-HCI 
buffer (pH 7.4) for 5-15 rain. Specificity of the immunohistochemical 
reaction was confirmed by the absence of staining in adjacent tissue 
sections incubated with antibody preabsorbed as previously described 
(Ueda et al, 1993). 
Double immunostaining was performed with antibodies against 
NACP and synaptophysin as described previously (Masliah et al., 
1991 b). After treatment with 0.1% Triton X-100 and 3% H202, sections 
were incubated for 1 hr with 5% normal horse serum (Vector Labs, 
Inc., Burlingame, CA), 10% NGS (Vector Labs, Inc.), and 2% BSA in 
PBS. They were then incubated for 18 hr at 4°C with the mixture of 
mouse monoclonal antibody against synaptophysin (SY38, Boehringer 
Mannheim, Indianapolis, IN; Wiedenmann and Franke, 1985) and rab- 
bit polyclonal antibodies, anti-NACP(1-9) or anti-NACP(131-140), in 
PBS containing 3% normal horse serum, NGS, and BSA. Sections 
were rinsed three times for 5 rain each in PBS, incubated for 1 hr 
with biotinylated goat anti-rabbit IgG in PBS containing 1% BSA, and 
rinsed three times for 5 min each in PBS. They were then incubated 
for 80 rain with Texas red-labeled avidin (Vector Labs, Inc.) and fluo- 
rescein isothiocyanate-labeled horse anti-mouse IgG antibody (Vec- 
tor Labs, Inc.) in PBS containing 1% BSA, and rinsed three times for 
5 min each in PBS. The double-immunolabeled sections were covered 
with glass coverslips with antifading medium (Vector Labs, Inc.). These 
sections were imaged with the Bio-Rad MRC-600 laser confocal scan- 
ning microscope mounted on a Zeiss Axiovert microscope (Masliah 
et al., 1991a, 1992b). This system permits the simultaneous analysis 
of double-labeled samples in the same optical plane. The digitized 
video images of serial 0.5 p.m optical sections were stored on an optical 
disk for subsequent processing and analysis. Electronically merged 
digital images were analyzed with the Image 1.43 program (Wayne 
Rasband, NIH) to calculate the percentage of presynaptic terminals 
that contain either one or both of the markers (Masliah et al., 1991b). 
For electron microscopic study of anti-NACP staining detected by 
DAB, 40 ~m vibratome sections were blocked with NGS (5%) and 
incubated overnight at 4°C with anti-NACP(131-140) (Masliah et al., 
1991 a). The sections were washed in PBS, incubated with biotinylated 
goat anti-rabbit IgG followed by avidin D-HRP (Vector ABC elite, Vec- 
tor Labs, Inc.), and reacted with DAB (0.2 mg/ml) in 50 mM Tris-HCI 
buffer (pH 7.4) with 0.001% H20~. To prevent the artifactual diffusion 
of the chromogen, the sections were incubated in 1% glutaraldehyde 
in 0.15 M cacodylate buffer before the DAB. Control experiments were 
performed by incubating sections with nonimrnune serum. The immu- 
nostained sections were postfixed for 20 min in 1% OsO4, dehydrated, 
and flat embedded in epoxy/Araldite. UItrathin sections were cut with 
a Leica Ultracut E ultramicrotorne and viewed with a 100 CX JEOL 
electron microscope. 
The vibratome sections for immunogold staining were embedded 
in Durcupan, and ultrathin sections were cut as above. The sections 
were treated with 1% NalO4 in water, 50 mM glycine in PBS, and 1% 
BSA in PBS, each for 4 min with rinsing in water between each step. 
Sections were incu bated with anti-NACP(131-140) antibody as above, 
rinsed with 1% BSA in PBS, incubated with a 1:30 dilution of 5 nm 
gold goat anti-rabbit IgG (Amersham) for 1 hr, and rinsed again. The 
immunogold-stained sections were postfixed with 1% glutaraldehyde 
in PBS for 3 min and counterstained with uranyl acetate and lead 
citrate before examination with an electron microscope as above. 
Biochemical Quantification of NACP and Synaptophysin 
Brains of young adult Sprague-Dawley rats weighing 250-300 g were 
separated into ten portions as follows: olfactory bulb, frontal cortex, 
striatum, hippocampus, hypothalamus, thalamus, midbrain, cerebel- 
lure, pons/medulla oblongata, and pituitary. Each portion was homoge- 
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nized as described earlier and used in Western blots for NACP and 
synaptophysin quantification. Protein (40 pg) from the particulate frac- 
tion (for synaptophysin quantitation) or from the cytosolic fraction (for 
NACP quantitation) was loaded on a 10% SDS-polyacrylamide gel 
and blotted to nitrocellulose membrane. The rabbit anti-NACP(131- 
140) antibody in PBS containing 1% BSA and 0.1% Tween-20 was 
used for NACP quantitation. For synaptophysin quantitation, the 
mouse monoclonal antibody against synaptophysin (SY38, Boehringer 
Mannheim), in PBS containing 1% BSA and 0.1% Tween-20, was used 
as the primary antibody, followed by rabbit anti-mouse IgG polyclonal 
antibody (Accurate Chemical and Scientific Corp., Westbury, NY) at 
the dilution of 1:2000 in PBS containing 3% BSA. After incubation 
with antibodies, blots were rinsed, incubated with 0.5 pCi/ml iodinated 
protein A, rinsed further, and apposed to Kodak X-Omat RP film at 
-80°C. Films were then developed with a Konica film developer and 
scanned with an LKB densitometer for quantitation of the NACP or 
synaptophysin bands. The exposure time was chosen so that the inten- 
sity of bands were in the OD range between 0.8 and 2.5, where the 
sensitivity of the film is relatively linear. 
NACP Homologies 
Computer homology search (FASTA program) was used for searching 
the DNA sequence database (European Molecular Biology Laboratory/ 
GenBank Libraries). Also, the BLAST network service at NCBI (Na- 
tional Center for Biotechnolegy Information, Bethesda, MD) was used 
to search for homologous sequences. 
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